Regeneron Pharmaceuticals, Inc. (REGN)

Market Cap	116.89B
Revenue (ttm)	13.10B
Net Income (ttm)	3.86B
Shares Out	108.37M
EPS (ttm)	33.86
PE Ratio	31.86
Forward PE	23.16
Dividend	n/a
Ex-Dividend Date	n/a

Volume	375,292
Open	1,067.54
Previous Close	1,064.19
Day's Range	1,067.54 - 1,091.31
52-Week Range	723.56 - 1,106.16
Beta	0.13
Analysts	Buy
Price Target	1,057.79 (-2.22%)
Earnings Date	Aug 1, 2024

About REGN

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 2, 1991
• Employees: 13,450
• Stock Exchange: NASDAQ
• Ticker Symbol: REGN

Financial Performance

In 2023, REGN's revenue was $13.12 billion, an increase of 7.76% compared to the previous year's $12.17 billion. Earnings were $3.95 billion, a decrease of -8.87%.

Analyst Forecast

According to 24 analysts, the average rating for REGN stock is "Buy." The 12-month stock price forecast is $1,057.79, which is a decrease of -2.22% from the latest price.

Price Target

$1,057.79

(-2.22% downside)

Analyst Consensus: Buy